False-Negative Rate of Direct Immunofluorescence on Lower Extremities in Bullous Pemphigoid.
Adult
Aged
Aged, 80 and over
Autoantibodies
/ analysis
Biomarkers
/ analysis
Biopsy
Complement C3
/ analysis
Databases, Factual
False Negative Reactions
Female
Fluorescent Antibody Technique, Direct
Humans
Immunoglobulin G
/ analysis
Infant
Lower Extremity
Male
Middle Aged
Pemphigoid, Bullous
/ diagnosis
Predictive Value of Tests
Reproducibility of Results
Retrospective Studies
Skin
/ immunology
Journal
The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
pubmed:
4
7
2020
medline:
7
10
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
Bullous pemphigoid (BP) is the most common autoimmune blistering disorder of the skin. It is typified by tense blisters with a subepidermal split and mixed dermal inflammatory infiltrate on histology. Biopsy of the perilesional skin for direct immunofluorescence (DIF) has become the gold standard in the diagnosis of BP. Currently there is a pervasive clinical opinion that the lower extremity is a site with a high false-negative rate (FNR) for DIF in the diagnosis of BP. This notion is primarily based on 2 early studies from the 1980s without more recent confirmatory studies. To readdress this question regarding the lower extremities, a retrospective study from 2012 to 2018 was performed in our institution that evaluated the FNR of DIF by an anatomical site in the diagnosis of BP. Cases of BP were identified using standard criteria (clinical and histological data reviewed in cases with negative DIF), and overall, 79 patients were included in the study. A total of 4 false-negative DIF biopsies were verified. Two negative DIF were from the lower extremity yielding a FNR of 10% compared with 4% on the trunk and 3% from the upper extremity, with no statistically significant difference by anatomical sites. Our study fails to demonstrate a high FNR of DIF from the lower extremity in the diagnosis of BP.
Identifiants
pubmed: 32618708
pii: 00000372-202101000-00007
doi: 10.1097/DAD.0000000000001710
doi:
Substances chimiques
Autoantibodies
0
Biomarkers
0
C3 protein, human
0
Complement C3
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-44Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999;354:667–672.
Korman NJ. Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy. Arch Dermatol. 1998;134:1137–1141.
Maize JC, Provost TT. Value of immunofluorescent techniques in studies of bullous disease. Am J Dermatopathol. 1983;5:67–72.
Weigand DA. Effect of anatomic region on immunofluorescence diagnosis of bullous pemphigoid. J Am Acad Dermatol. 1985;12:274–278.
Weigand DA, Clements MK. Direct immunofluorescence in bullous pemphigoid: effects of extent and location of lesions. J Am Acad Dermatol. 1989;20:437–440.
Fudge JG, Crawford RI. Bullous pemphigoid: a 10-year study of discordant results on direct immunofluorescence. J Cutan Med Surg. 2018;22:472–475.